Effect of Deferasirox on Patients With Cardiac MRI T2* < 20 Msec
NCT00879242 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2016-12-12
Summary
This study will assess the safety and efficacy of deferasirox in patients with cardiac MRI T2\* \< 20 msec.
Conditions
- Beta Thalassemia Transfusion Dependent
Interventions
- DRUG
-
Deferasirox
Dispersible tables of 125, 250 and 500 mg at the dose of 30 mg/kg/day, oral administration.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis Pharmaceuticals · Novartis Pharmaceuticals
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 10 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-02-28
- Primary Completion
- 2011-05-31
Countries
- Italy
Study Locations
More Related Trials
-
Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet
NCT02993224 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia
NCT01709838 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload
NCT01459718 ·Status: TERMINATED ·Phase: PHASE2
-
Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study
NCT00873041 ·Status: COMPLETED ·Phase: PHASE2
-
Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload
NCT00379483 ·Status: COMPLETED ·Phase: PHASE2
-
This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.
NCT01250951 ·Status: COMPLETED ·Phase: PHASE4
-
Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients
NCT00303329 ·Status: COMPLETED ·Phase: PHASE2
-
An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years Old
NCT01724138 ·Status: WITHDRAWN ·Phase: PHASE4
-
Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)
NCT00171301 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy of Deferasirox in Patients With Transfusion Dependent Iron Overload - a Non-comparative Extension Study
NCT01033747 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias
NCT00061763 ·Status: COMPLETED ·Phase: PHASE2
-
Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS
NCT03920657 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients
NCT00110266 ·Status: COMPLETED ·Phase: PHASE2
-
Observation of Patients With Transfusional Hemosiderosis Treatment With Deferasirox
NCT01394029 ·Status: COMPLETED
-
Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis
NCT00000595 ·Status: COMPLETED ·Phase: PHASE2
-
Retrospective Evaluation of Adult and Pediatric Transfusion-dependent Patients Treated With Deferasirox Therapy
NCT01874405 ·Status: COMPLETED
-
Evaluation of Real-World Data on Ropeginterferon Alfa-2b in Patients With Polycythemia Vera: Insights From a Multicenter Study
NCT07282132 ·Status: NOT_YET_RECRUITING
-
Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome
NCT02943668 ·Status: TERMINATED ·Phase: PHASE2
-
Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major
NCT00103753 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron Overload
NCT01254227 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
NCT02125877 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent (NTD) Beta-Thalassemia
NCT03271541 ·Status: COMPLETED ·Phase: PHASE2
-
Atrial Fibrillation in Beta-Thalassemia
NCT05508932 ·Status: RECRUITING
-
Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases
NCT00115349 ·Status: TERMINATED ·Phase: PHASE2
-
Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy
NCT01956799 ·Status: COMPLETED